Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 4/2013

01-07-2013 | Case Report

Primary hyperparathyroidism in a patient with familial hypocalciuric hypercalcaemia due to a novel mutation in the calcium-sensing receptor gene

Authors: Aoife M. Egan, James Ryan, Mardiana A. Aziz, Tadhg P. O’Dwyer, Maria M. Byrne

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2013

Login to get access

Abstract

We describe the clinical and genetic findings in pedigree with a novel mutation in the calcium sensing receptor (CaSR) gene and the unusual coexistence of primary hyperparathyroidism (HPT) and familial hypocalciuric hypercalcaemia (FHH) and its clinical management. The occurrence of both FHH and primary HPT in the same patient has been described rarely. Our pedigree has a novel mutation in the CaSR gene. Parathyroidectomy led to a reduction, but not normalization of the calcium levels in the patient identified as having HPT. The coexistence of HPT and FHH was considered in this patient as her calcium and PTH levels were rising with time. Surgical resection of her parathyroid adenoma resulted in reduction of her calcium levels to above normal and significant reduction in her symptoms of fatigue and low mood.
Literature
1.
go back to reference Thakker RV (2004) Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium 35:275–282PubMedCrossRef Thakker RV (2004) Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium 35:275–282PubMedCrossRef
2.
go back to reference Carmliet G, Cromphat SV, Daci E, Maes C, Bouillon R (2003) Disorders of calcium homeostasis. Best Pract Res Clin Endocrinol Metab 17:529–546CrossRef Carmliet G, Cromphat SV, Daci E, Maes C, Bouillon R (2003) Disorders of calcium homeostasis. Best Pract Res Clin Endocrinol Metab 17:529–546CrossRef
3.
go back to reference Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572–581PubMedCrossRef Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572–581PubMedCrossRef
4.
go back to reference D’Souza-Li L, Yang B, Canaff L, Vai M, Hanley DA, Bastepe M, Salisbury SR, Brown EM, Cole DEC, Hendy GN (2002) Identification and functional characterisation of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia. J Clin Endocrinol Metab 87:1309–1318PubMedCrossRef D’Souza-Li L, Yang B, Canaff L, Vai M, Hanley DA, Bastepe M, Salisbury SR, Brown EM, Cole DEC, Hendy GN (2002) Identification and functional characterisation of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcaemia and autosomal dominant hypocalcaemia. J Clin Endocrinol Metab 87:1309–1318PubMedCrossRef
5.
go back to reference Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG (1993) Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297–1303PubMedCrossRef Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG (1993) Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297–1303PubMedCrossRef
6.
go back to reference Bouschet T, Martin S, Henley JM (2008) Regulation of calcium-sensing-receptor trafficking and cell-surface expression by GPCRs and RAMPs. Trends Pharmacol Sci 29:633–639PubMedCrossRef Bouschet T, Martin S, Henley JM (2008) Regulation of calcium-sensing-receptor trafficking and cell-surface expression by GPCRs and RAMPs. Trends Pharmacol Sci 29:633–639PubMedCrossRef
7.
go back to reference Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR (2012) Primary hyperparathyroidism and FHH: relationships and Clinical implications. Endocr Pract 18:412–417PubMedCrossRef Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR (2012) Primary hyperparathyroidism and FHH: relationships and Clinical implications. Endocr Pract 18:412–417PubMedCrossRef
8.
go back to reference Burski K, Torjussen B, Paulsen AQ, Boman H, Bollerslev J (2002) Familial hypocalciuric hypercalcemia: coincidence or causality? J Clin Endocrinol Metab 87:1015–1016PubMedCrossRef Burski K, Torjussen B, Paulsen AQ, Boman H, Bollerslev J (2002) Familial hypocalciuric hypercalcemia: coincidence or causality? J Clin Endocrinol Metab 87:1015–1016PubMedCrossRef
9.
go back to reference Brachet C, Boros E, Tenoutasse S, Lissens W, Andry G, Martin P, Bergmann P, Heinrichs C (2009) Association of parathyroid adenoma and familial hypocalciuric hypercalcaemia in a teenager. Eur J Endocrinol 161:207–210PubMedCrossRef Brachet C, Boros E, Tenoutasse S, Lissens W, Andry G, Martin P, Bergmann P, Heinrichs C (2009) Association of parathyroid adenoma and familial hypocalciuric hypercalcaemia in a teenager. Eur J Endocrinol 161:207–210PubMedCrossRef
10.
go back to reference Thorgeirsson U, Costa J, Marx SJ (1981) The parathyroid glands in familial hypocalciuric hypercalcaemia. Hum Pathol 12:229–237PubMedCrossRef Thorgeirsson U, Costa J, Marx SJ (1981) The parathyroid glands in familial hypocalciuric hypercalcaemia. Hum Pathol 12:229–237PubMedCrossRef
11.
go back to reference Bilezikan JP, Khan AA, Potts JT Jr, on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 94:335–339CrossRef Bilezikan JP, Khan AA, Potts JT Jr, on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 94:335–339CrossRef
12.
go back to reference Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, Clemens TL, Bilezikian JP (1990) Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 89:327–334PubMedCrossRef Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, Clemens TL, Bilezikian JP (1990) Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 89:327–334PubMedCrossRef
13.
go back to reference Marx SJ, Stock JL, Attie MF, Downs RW Jr, Gardner DG, Brown EM, Speigel AM, Doppman JL, Brennan MF (1980) Familial hypocalciuric hypercalcaemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 92:351–356PubMedCrossRef Marx SJ, Stock JL, Attie MF, Downs RW Jr, Gardner DG, Brown EM, Speigel AM, Doppman JL, Brennan MF (1980) Familial hypocalciuric hypercalcaemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 92:351–356PubMedCrossRef
14.
go back to reference Frank-Raue K, Leidig-Bruckner G, Haag C, Schulze E, Lorenz A, Schmitz-Winnenthal H, Raue R (2011) Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol 75:50–55CrossRef Frank-Raue K, Leidig-Bruckner G, Haag C, Schulze E, Lorenz A, Schmitz-Winnenthal H, Raue R (2011) Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol 75:50–55CrossRef
15.
go back to reference Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J (2000) Familial hypercalcaemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042–2047PubMedCrossRef Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J (2000) Familial hypercalcaemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042–2047PubMedCrossRef
16.
go back to reference Yabuta T, Miyauchi A, Inoue H, Yoshida H, Hirokawa M, Amino N (2009) A patient with primary hyperparathyroidism associated with familial hypocalciuric hypercalcaemia induced by a novel germline CaSR mutation. Asian J Surg 32:118–122PubMedCrossRef Yabuta T, Miyauchi A, Inoue H, Yoshida H, Hirokawa M, Amino N (2009) A patient with primary hyperparathyroidism associated with familial hypocalciuric hypercalcaemia induced by a novel germline CaSR mutation. Asian J Surg 32:118–122PubMedCrossRef
Metadata
Title
Primary hyperparathyroidism in a patient with familial hypocalciuric hypercalcaemia due to a novel mutation in the calcium-sensing receptor gene
Authors
Aoife M. Egan
James Ryan
Mardiana A. Aziz
Tadhg P. O’Dwyer
Maria M. Byrne
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2013
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-012-0399-4

Other articles of this Issue 4/2013

Journal of Bone and Mineral Metabolism 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.